PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07D 223/16, 405/04, 409/04, A61K 31/55, A61P 25/16	A1	(11) International Publication Number:	WO 00/49000
		(43) International Publication Date:	24 August 2000 (24.08.00)

(21) International Application Number: PCT/GB00/00570

(22) International Filing Date: 17 February 2000 (17.02.00)

(30) Priority Data:
9903671.7 17 February 1999 (17.02.99) GB

(71) Applicant *(for all designated States except US)*: CENES LIMITED [GB/GB]; Compass House, Vision Park, Chivers Way, Histon, Cambridge CB4 4ZR (GB).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: TILBROOK, Gary [GB/GB]; CeNes Limited, Vision Park, Chivers Way, Histon, Cambridge CB4 4ZR (GB).


(74) Agent: DAVIES, Jonathan, Mark; Reddie & Grose, 16 Theobalds Road, London WC1X 8PL (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

G00001

(54) Title: DOPAMINE D1 RECEPTOR AGONIST COMPOUNDS



(I)

(57) Abstract

The invention provides 2,3,4,5–tetrahydro–1H–3–benzazepines of general formula (I) wherein: R^1 is hydrogen, halogen, C_1–C_4 alkyl, or CF_3; R^2 is hydrogen, methyl, or lower alkenyl of 3–5 carbon atoms; R^3 and R^4 together form a furan, dihydrofuran, thiophene, dihydrothiophene, cyclopentane or cyclohexane ring and R^5 is hydrogen or R^4 and R^5 together form a furan, dihydrofuran, thiophene, dihydrothiophene, cyclopentane or cyclohexane ring and R^3 is hydrogen; R^6 is hydrogen, halogen, CF_3, CN, NO_2 or NH_2; R^7 is hydrogen, halogen, CF_3, CN, NO_2 or NH_2. The specific combination of substituents: R_1 = H, R_2 = H and R_4 and R_5 together forming a cyclohexane ring is excluded, namely 1–(5,6,7,8–tetrahydronaphthalen–2–yl)–2,3,4,5–tetrahydro–1H–benzol[d]azepine–7,8–diol. The compounds of the invention provide therapeutic agents that selectively interact positively with postsynaptic dopamine D1 receptors in the striatum, directly or in–directly (termed dopamine D1 agonists) and are particularly valuable as anti–Parkinsonian agents.